Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 13, 2019updated 23 Dec 2019 9:27am

Tocagen’s cancer drug fails to improve survival in glioma trial

A Phase III clinical trial performed by Tocagen to assess its cancer immunotherapy, Toca 511 & Toca FC, has failed to meet the primary endpoint of overall survival in patients with recurrent high grade glioma (HGG), a form of brain cancer.

A Phase III clinical trial performed by Tocagen to assess its cancer immunotherapy, Toca 511 & Toca FC, has failed to meet the primary endpoint of overall survival in patients with recurrent high grade glioma (HGG), a form of brain cancer.

The immunotherapy is a two-part product made of an investigational retroviral replicating vector (RRV) Toca 511 and investigational oral small molecule Toca FC.

Toca 511 specifically infects cancer cells and delivers a gene for the cytosine deaminase (CD) enzyme.

Toca FC is a 5-fluorocytosine (5-FC) prodrug that converts into an anti-cancer drug called 5-fluorouracil (5-FU) upon encounter with CD. 5-FU destroys cancer cells and immune-suppressive myeloid cells.

“We will be conducting a thorough analysis of the data including molecular analyses and pre-planned subgroups.”

The multi-centre, randomised, open-label Phase III trial, named Toca 5, compared the cancer immunotherapy to standard of care in more than 400 patients undergoing resection.

According to the study results, Toca 511 & Toca FC did not meet the primary endpoint, demonstrating 11.1 months of median overall survival versus 12.2 months with standard of care.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

No meaningful difference was observed in all secondary endpoints between the study groups.

The secondary outcomes included durable response rate, durable clinical benefit rate, and overall survival at 12 months.

Tocagen CEO Marty Duvall said: “While the Toca 5 trial results are disappointing, we will be conducting a thorough analysis of the data including molecular analyses and pre-planned subgroups. In addition, we will be conducting an operational review.”

These results come shortly after Bristol-Myers Squibb’s Opdivo (nivolumab) combination therapy failed to meet the primary endpoint of progression-free survival (PFS) in patients with glioblastoma multiforme (GBM), also a type of brain cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU